search
Back to results

L-arginine and Brown Adipose Tissue (ArgMB)

Primary Purpose

Adipose Tissue, Brown, Glucose Intolerance, Nitric Oxide

Status
Unknown status
Phase
Phase 3
Locations
Netherlands
Study Type
Interventional
Intervention
L-arginine
Placebo
Sponsored by
Maastricht University Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Adipose Tissue, Brown

Eligibility Criteria

35 Months - 50 Years (Child, Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Caucasian or South Asian ethnicity
  • Age: 35-50 years
  • Gender: male
  • BMI: 25-30 kg/m2
  • Plasma glucose levels 2 h after OGTT between 7.8 and 11 mM (e.g. impaired glucose tolerance) or Fasting plasma glucose levels > 5.5 mM
  • Good general health

Exclusion Criteria:

  • Type 2 diabetes (determined on basis of oral glucose tolerance test (OGTT))
  • BMI > 30 kg/m2
  • Plasma glucose levels 2 h after OGTT < 7.8 mM
  • Plasma L-arginine levels < 41 or > 114 uM
  • Use of beta-blockers (these inhibit BAT activity) < 1 month before start of study or during study
  • Systolic blood pressure < 90 mmHg
  • Haematocrit < 0.41 or > 0.51 l/l
  • Haemoglobin < 8.5 or > 11.0
  • Creatinine (enzymatic method) < 45 or > 100 μmol/L
  • ASAT > 45 U/L
  • ALAT > 50 U/L
  • Alkaline phosphatase > 125 U/L
  • Gamma GT > 45 U/L
  • Participation in an intensive weight-loss program or vigorous exercise program during the last year before the start of the study
  • Abuse of drugs and/or alcohol
  • Hyperthyroidism or hypothyroidism
  • Participation in earlier research or medical examinations that included PET-CT scanning
  • Psychologically unstable subjects (as judged by the treating medical specialist)
  • Subjects with mental retardation (as judged by the treating medical specialist)
  • Subjects with severe behaviour disorders (as judged by the treating medical specialist)

Sites / Locations

  • Maastricht University Medical Center +Recruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

L-arginine

Placebo

Arm Description

Subjects will receive 9 gram of L-arginine per day in three gifts (3dd 3 gram) during 6 weeks.

Subjects will receive 9 gram of placebo per day in three gifts (3 dd 3 gram) during 6 weeks.

Outcomes

Primary Outcome Measures

Standard uptake value of Brown adipose tissue
Glucose uptake by brown adiopse tissue will be assessed by cold-induced 18F-FDG PET-CT scan
Energy expenditure
Energy expenditure will be determined by means of indirect calorimetrie
Fat mass
Fat mass will be determined by DEXA scan

Secondary Outcome Measures

Body temperatures
Skin and core body temperatures as well as gradients will be assessed by means of iButtons and ingestion of a telemetric pill, respectively.
Skin perfusion and endothelial-dependent and independent vasodilation
This will be measured by means of Laser Doppler Flowmetry (LDF) and iontophoresis
Skeletal muscle mitochondrial respiration/uncoupling
This will be determined in muscle biopsies by using the Oroboros 2k Oxygraph instrument present in our laboratory .
Brown adipocyte recruitment and inflammation in WAT
This will be measured in subcutaneous WAT biopsies by assessing mRNA expression via real time polymerase-chain reaction (RT-PCR) and protein content by immunohistochemical stainings.
Blood parameters
Venous blood will be drawn by means of a catheter placed in the antecubital vein of the underarm. By using radioimmunoassay, high performance liquid chromotogaphy (HPLC) and enzyme-linked immunosorbent assay (ELISA), blood parameters (i.e. lipids, glucose, inflammatory markers and endothelial activation markers) will be analyzed. In addition, we will perform DNA analyses from blood.

Full Information

First Posted
November 11, 2014
Last Updated
November 13, 2014
Sponsor
Maastricht University Medical Center
Collaborators
Leiden University Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT02291458
Brief Title
L-arginine and Brown Adipose Tissue
Acronym
ArgMB
Official Title
The Effect of L-arginine on Brown Adipose Tissue Metabolism in South Asian and White Caucasian Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
November 2014
Overall Recruitment Status
Unknown status
Study Start Date
November 2014 (undefined)
Primary Completion Date
October 2015 (Anticipated)
Study Completion Date
December 2015 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Maastricht University Medical Center
Collaborators
Leiden University Medical Center

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The South Asian population is facing an epidemic of type 2 diabetes, of which the underlying cause is still unknown. It is currently hypothesized that an ethnic susceptibility towards a disturbed energy metabolism may underlie this disadvantageous metabolic phenotype. In line with this, the investigators recently discovered that Dutch South Asian subjects have 32% lower resting energy expenditure (REE) and 34% lower energy-combusting brown adipose tissue (BAT) compared to matched white Caucasians. Nitric oxide (NO) was recently shown to be crucial for BAT development and, interestingly, South Asians have diminished NO bioavailability. Thus, the disadvantageous metabolic phenotype in South Asians may be caused by diminished NO bioavailability resulting in lower BAT volume. Therefore, the investigators hypothesize that increasing NO generation in the body by administration of L-arginine, the precursor of NO, will improve their metabolic phenotype by increasing BAT volume, thereby increasing REE and clearance of triglycerides and glucose by BAT. To investigate this, the investigators will perform a randomized placebo-controlled multicenter cross-over study in moderately obese Dutch South Asians and matched white Caucasians. Subjects will receive L-arginine (9 gram/day) or placebo for 6 weeks, followed by a wash-out period of 4 weeks and then again 6 weeks of one of either treatments. At the end of both treatment periods, a cold-induced PET-CT scan will be performed. Furthermore, muscle and fat biopsies will be obtained and thermoregulation will be assessed.
Detailed Description
Rationale: The South Asian population originally descends from the Indian subcontinent and represents approximately 20% of the total world population. This population is facing an epidemic of type 2 diabetes, of which the underlying cause is still unknown. A high prevalence of a disadvantageous metabolic phenotype, consisting of obesity, insulin resistance and dyslipidemia, may at least in part contribute to this excess risk. It is currently hypothesized that an ethnic susceptibility towards a disturbed energy metabolism may underlie this disadvantageous metabolic phenotype. In line with this, the investigators recently discovered that Dutch South Asian subjects have 32% lower resting energy expenditure (REE) and 34% lower energy-combusting brown adipose tissue (BAT) compared to matched white Caucasians. Nitric oxide (NO) was recently shown to be crucial for BAT development and, interestingly, South Asians have diminished NO bioavailability. Thus, the disadvantageous metabolic phenotype in South Asians may be caused by diminished NO bioavailability resulting in lower BAT volume. Therefore, the investigators hypothesize that increasing NO generation in the body by administration of L-arginine, the precursor of NO, will improve their metabolic phenotype by increasing BAT volume, thereby increasing REE and clearance of triglycerides and glucose by BAT. Objectives: The primary objectives are: 1) to determine the effect of L-arginine on glucose uptake by brown adipose tissue and to assess whether the effect differs between South Asian and white Caucasian subjects; 2) to determine the effect of L-arginine on whole body energy expenditure and to assess whether the effect differs between South Asian and white Caucasian subjects; 3) to determine the effect of L-arginine on fat mass and to assess whether the effect differs between South Asian and white Caucasian subjects. Study design: A randomized placebo-controlled multicenter cross-over study will be performed in moderately obese Dutch South Asians and matched white Caucasians. Subjects will receive L-arginine (9 gram/day) or placebo for 6 weeks, followed by a wash-out period of 4 weeks and then again 6 weeks of one of either treatments. At the end of both treatment periods, a cold-induced PET-CT scan will be performed. Furthermore, muscle and fat biopsies will be obtained, thermoregulation will be assessed, an oral glucose tolerance will be performed and the investigators will assess NO-dependent and independent vasodilation by means of iontophoresis. Study population: Mildly obese (BMI 25-30 kg/m2) pre-diabetic male volunteers of South Asian and white Caucasian descent aged between 35-50 years. Intervention: The intervention will consist of administration of 9 grams of L-arginine per day in three gifts (3dd 3 gram).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Adipose Tissue, Brown, Glucose Intolerance, Nitric Oxide

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
26 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
L-arginine
Arm Type
Experimental
Arm Description
Subjects will receive 9 gram of L-arginine per day in three gifts (3dd 3 gram) during 6 weeks.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Subjects will receive 9 gram of placebo per day in three gifts (3 dd 3 gram) during 6 weeks.
Intervention Type
Drug
Intervention Name(s)
L-arginine
Other Intervention Name(s)
Argimax
Intervention Description
9 gram L-arginine / day for 6 weeks
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
9 gram placebo / day for 6 weeks
Primary Outcome Measure Information:
Title
Standard uptake value of Brown adipose tissue
Description
Glucose uptake by brown adiopse tissue will be assessed by cold-induced 18F-FDG PET-CT scan
Time Frame
6 weeks
Title
Energy expenditure
Description
Energy expenditure will be determined by means of indirect calorimetrie
Time Frame
6 weeks
Title
Fat mass
Description
Fat mass will be determined by DEXA scan
Time Frame
6 weeks
Secondary Outcome Measure Information:
Title
Body temperatures
Description
Skin and core body temperatures as well as gradients will be assessed by means of iButtons and ingestion of a telemetric pill, respectively.
Time Frame
6 weeks
Title
Skin perfusion and endothelial-dependent and independent vasodilation
Description
This will be measured by means of Laser Doppler Flowmetry (LDF) and iontophoresis
Time Frame
6 weeks
Title
Skeletal muscle mitochondrial respiration/uncoupling
Description
This will be determined in muscle biopsies by using the Oroboros 2k Oxygraph instrument present in our laboratory .
Time Frame
6 weeks
Title
Brown adipocyte recruitment and inflammation in WAT
Description
This will be measured in subcutaneous WAT biopsies by assessing mRNA expression via real time polymerase-chain reaction (RT-PCR) and protein content by immunohistochemical stainings.
Time Frame
6 weeks
Title
Blood parameters
Description
Venous blood will be drawn by means of a catheter placed in the antecubital vein of the underarm. By using radioimmunoassay, high performance liquid chromotogaphy (HPLC) and enzyme-linked immunosorbent assay (ELISA), blood parameters (i.e. lipids, glucose, inflammatory markers and endothelial activation markers) will be analyzed. In addition, we will perform DNA analyses from blood.
Time Frame
6 weeks

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
35 Months
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Caucasian or South Asian ethnicity Age: 35-50 years Gender: male BMI: 25-30 kg/m2 Plasma glucose levels 2 h after OGTT between 7.8 and 11 mM (e.g. impaired glucose tolerance) or Fasting plasma glucose levels > 5.5 mM Good general health Exclusion Criteria: Type 2 diabetes (determined on basis of oral glucose tolerance test (OGTT)) BMI > 30 kg/m2 Plasma glucose levels 2 h after OGTT < 7.8 mM Plasma L-arginine levels < 41 or > 114 uM Use of beta-blockers (these inhibit BAT activity) < 1 month before start of study or during study Systolic blood pressure < 90 mmHg Haematocrit < 0.41 or > 0.51 l/l Haemoglobin < 8.5 or > 11.0 Creatinine (enzymatic method) < 45 or > 100 μmol/L ASAT > 45 U/L ALAT > 50 U/L Alkaline phosphatase > 125 U/L Gamma GT > 45 U/L Participation in an intensive weight-loss program or vigorous exercise program during the last year before the start of the study Abuse of drugs and/or alcohol Hyperthyroidism or hypothyroidism Participation in earlier research or medical examinations that included PET-CT scanning Psychologically unstable subjects (as judged by the treating medical specialist) Subjects with mental retardation (as judged by the treating medical specialist) Subjects with severe behaviour disorders (as judged by the treating medical specialist)
Facility Information:
Facility Name
Maastricht University Medical Center +
City
Maastricht
State/Province
Limburg
ZIP/Postal Code
6229 ER
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mariette Boon, PhD
Phone
+31648126425
Email
m.boon@maastrichtuniversity.nl
First Name & Middle Initial & Last Name & Degree
Wouter van Marken Lichtenbelt, PhD
Phone
Tel: +31 43 388 1629
Email
markenlichtenbelt@maastrichtuniversity.nl

12. IPD Sharing Statement

Citations:
PubMed Identifier
31701693
Citation
Janssen LGM, Van Dam AD, Hanssen MJW, Kooijman S, Nahon KJ, Reinders H, Jazet IM, Van Marken Lichtenbelt WD, Rensen PCN, Appelman-Dijkstra NM, Boon MR. Higher Plasma Sclerostin and Lower Wnt Signaling Gene Expression in White Adipose Tissue of Prediabetic South Asian Men Compared with White Caucasian Men. Diabetes Metab J. 2020 Apr;44(2):326-335. doi: 10.4093/dmj.2019.0031. Epub 2019 Oct 31.
Results Reference
derived
PubMed Identifier
30377712
Citation
Boon MR, Hanssen MJW, Brans B, Hulsman CJM, Hoeks J, Nahon KJ, Bakker C, van Klinken JB, Havekes B, Schaart G, Jazet IM, Rensen PCN, van Marken Lichtenbelt WD. Effect of L-arginine on energy metabolism, skeletal muscle and brown adipose tissue in South Asian and Europid prediabetic men: a randomised double-blinded crossover study. Diabetologia. 2019 Jan;62(1):112-122. doi: 10.1007/s00125-018-4752-6. Epub 2018 Oct 30.
Results Reference
derived
PubMed Identifier
30070030
Citation
Nahon KJ, Kantae V, den Haan R, Hanssen MJW, Harms AC, van der Stelt M, Hankemeier T, Jazet IM, van Marken Lichtenbelt WD, Rensen PCN, Boon MR. Gene Expression of Endocannabinoid System Components in Skeletal Muscle and Adipose Tissue of South Asians and White Caucasians with Overweight. Obesity (Silver Spring). 2018 Aug;26(8):1332-1337. doi: 10.1002/oby.22245. Epub 2018 Aug 1.
Results Reference
derived

Learn more about this trial

L-arginine and Brown Adipose Tissue

We'll reach out to this number within 24 hrs